Published in Ther Clin Risk Manag on May 04, 2009
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Strategies to improve long-term outcomes after renal transplantation. N Engl J Med (2002) 6.76
Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med (2000) 6.65
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
Immunosuppressive drugs for kidney transplantation. N Engl J Med (2004) 4.09
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4.04
Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med (1994) 2.93
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation (1999) 2.81
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 2.67
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1996) 2.61
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant (2007) 2.46
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 2.38
Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell (1996) 2.31
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation (1999) 2.27
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant (2004) 2.17
Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation (2000) 1.90
Transplantation 50 years later--progress, challenges, and promises. N Engl J Med (2004) 1.86
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant (2006) 1.83
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol (2007) 1.76
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant (2007) 1.76
Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation (2006) 1.65
Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation (1999) 1.59
Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation (1997) 1.52
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant (2004) 1.50
Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant (2006) 1.44
A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation (2003) 1.41
Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf (2001) 1.39
Analyses of the UNOS Scientific Renal Transplant Registry at three years--early events affecting transplant success. Transplantation (1992) 1.37
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 1.33
Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant (2003) 1.31
Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol (1996) 1.29
Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc (1990) 1.25
Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol (1987) 1.21
Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit (2001) 1.17
Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit (1999) 1.15
A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation (1999) 1.14
Mycophenolate mofetil. Lancet (1996) 1.12
Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem (1995) 1.11
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol (2005) 1.06
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit (2005) 1.04
A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1998) 1.04
Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem (2001) 1.03
Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant (2004) 1.03
The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation (2005) 1.03
A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet (2005) 1.01
Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc (1993) 0.99
Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant (2005) 0.98
Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation (2005) 0.97
Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant (2008) 0.96
Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant (2007) 0.96
Mycophenolic acid: an anti-cancer compound with unusual properties. Nature (1969) 0.96
Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol (2002) 0.95
Update in renal transplantation. Arch Intern Med (2004) 0.94
Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation (2003) 0.93
Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1997) 0.92
Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant (2003) 0.92
Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation (2000) 0.90
Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation (2003) 0.89
Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation (2000) 0.89
Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation (2007) 0.89
Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant (2004) 0.89
Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation (2006) 0.88
Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transpl Immunol (2008) 0.86
Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation (1998) 0.85
Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int (2001) 0.85
Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation (2001) 0.82
Therapeutic monitoring of mycophenolic acid: is there clinical utility? Am J Transplant (2007) 0.82
Chronic graft loss. Immunological and non-immunological factors. Contrib Nephrol (2005) 0.82
The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol (2001) 0.81
The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. Am J Transplant (2003) 0.81
Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit (2000) 0.81
Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Transplantation (1996) 0.81
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Transplant Proc (2007) 0.81
Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int (2003) 0.80
Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation (2001) 0.80
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol (2006) 0.80
Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol (2006) 0.78
Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation (2005) 0.78
Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int (2002) 0.78
Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx. Lancet (1946) 0.77
Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective, multicenter, randomized study. Transplantation (2002) 0.77
Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation (1998) 0.76
Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study. Transplant Proc (2006) 0.76
Chronic renal allograft dysfunction: a role for mycophenolate mofetil? Transplantation (2000) 0.76
Cyclosporine withdrawal in stable renal transplant recipients. Transplantation (2003) 0.76
Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplant Proc (2007) 0.76
Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc (2005) 0.75
Acute renal failure. N Engl J Med (1996) 8.83
Ecological forecasts: an emerging imperative. Science (2001) 5.18
Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology (2010) 2.37
Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. Science (2014) 1.92
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol (2010) 1.70
Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease. Lancet (1996) 1.66
Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum (2000) 1.56
Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis (1990) 1.50
Comparison of continuous and intermittent renal replacement therapy for acute renal failure. Nephrol Dial Transplant (2005) 1.50
Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation (2001) 1.44
Sodium retention and ascites formation in a cholestatic mice model: role of aldosterone and mineralocorticoid receptor? Hepatology (2007) 1.43
Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation (2001) 1.38
Referral patterns and outcomes in noncritically ill patients with hospital-acquired acute kidney injury. Clin J Am Soc Nephrol (2011) 1.27
Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat (1984) 1.21
Upregulation of BDNF mRNA expression in the barrel cortex of adult mice after sensory stimulation. J Neurosci (1996) 1.21
From global to local genetic structuring in the red gorgonian Paramuricea clavata: the interplay between oceanographic conditions and limited larval dispersal. Mol Ecol (2011) 1.12
Ethanol exposure enhances cell death in the developing cerebral cortex: role of brain-derived neurotrophic factor and its signaling pathways. J Neurosci Res (2002) 1.08
Age-dependent effects of secreted Semaphorins 3A, 3F, and 3E on developing hippocampal axons: in vitro effects and phenotype of Semaphorin 3A (-/-) mice. Mol Cell Neurosci (2001) 1.05
De novo collapsing glomerulopathy in renal allografts. Transplantation (1998) 1.05
Viruses and thrombotic microangiopathy. Transplantation (1999) 1.05
Phylogeography of the European spiny lobster (Palinurus elephas): Influence of current oceanographical features and historical processes. Mol Phylogenet Evol (2008) 1.04
Population structure within and between subspecies of the Mediterranean triplefin fish Tripterygion delaisi revealed by highly polymorphic microsatellite loci. Mol Ecol (2006) 1.04
A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J Clin Endocrinol Metab (2003) 1.03
Cytotoxicity and apoptosis in human renal allografts: identification, distribution, and quantitation of cells with a cytotoxic granule protein GMP-17 (TIA-1) and cells with fragmented nuclear DNA. Lab Invest (1997) 1.03
Effect of sodium loading/depletion on renal oxygenation in young normotensive and hypertensive men. Hypertension (2010) 1.03
Matching genetics with oceanography: directional gene flow in a Mediterranean fish species. Mol Ecol (2011) 1.02
Reference values and factors associated with renal resistive index in a family-based population study. Hypertension (2013) 1.00
Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation (1998) 0.99
Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med (1999) 0.99
Phylogeography and speciation of colour morphs in the colonial ascidian Pseudodistoma crucigaster. Mol Ecol (2004) 0.99
Strong population structure in the marine sponge Crambe crambe (Poecilosclerida) as revealed by microsatellite markers. Mol Ecol (2004) 0.98
Outpatient treatment of patients with uncomplicated acute diverticulitis. Colorectal Dis (2010) 0.98
Non-invasive monitoring of renal oxygenation using BOLD-MRI: a reproducibility study. NMR Biomed (2006) 0.97
Selection of lactobacilli for chicken probiotic adjuncts. J Appl Microbiol (1998) 0.97
Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol (1999) 0.97
Glia and fetal alcohol syndrome. Neurotoxicology (2001) 0.96
Effect of insulin-like growth factor I on in vivo intestinal absorption of D-galactose in cirrhotic rats. Am J Physiol (1999) 0.96
Sirolimus-induced acneiform eruption. Dermatology (2005) 0.96
Genetic polymorphisms in Spanish rheumatoid arthritis patients: an association and linkage study. Genes Immun (2003) 0.95
Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I. Gastroenterology (1997) 0.95
Primary colonic angiosarcoma as a cause of massive lower gastrointestinal bleeding. Rev Esp Enferm Dig (2010) 0.94
The telomeric part of the HLA region predisposes to rheumatoid arthritis independently of the class II loci. Hum Immunol (2001) 0.94
Successful use of tissue plasminogen activator in catheter-related intracardiac thrombus of a premature infant. Am J Perinatol (2003) 0.93
Renal perfusion evaluation with contrast-enhanced ultrasonography. Nephrol Dial Transplant (2011) 0.93
Donors with positive blood culture: could they transmit infections to the recipients? Transplant Proc (2005) 0.93
Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation (2002) 0.92
Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.90
Renal haemosiderosis: an unusual presentation of acute renal failure in a patient following heart valve prosthesis. Nephrol Dial Transplant (2004) 0.89
The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J Neurol Sci (2001) 0.88
Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc (2005) 0.88
Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol (2001) 0.88
Blockade of the renin-angiotensin system and renal tissue oxygenation as measured with BOLD-MRI in patients with type 2 diabetes. Diabetes Res Clin Pract (2012) 0.88
Evolving trends in liver transplantation: an outcome and charge analysis. Transplantation (1999) 0.88
Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly (2009) 0.87
SNP development from RNA-seq data in a nonmodel fish: how many individuals are needed for accurate allele frequency prediction? Mol Ecol Resour (2013) 0.87
Intrarenal arterial aneurysms with haematuria in a patient with tuberous sclerosis complex. Nephrol Dial Transplant (2005) 0.87
Molecular basis of hereditary C1q deficiency associated with SLE and IgA nephropathy in a Turkish family. Kidney Int (1996) 0.86
Renal tissue oxygenation in essential hypertension and chronic kidney disease. Int J Hypertens (2013) 0.86
Expression of NGF and NT3 mRNAs in hippocampal interneurons innervated by the GABAergic septohippocampal pathway. J Neurosci (1996) 0.86
Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria. J Am Soc Nephrol (2002) 0.86
Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol (2003) 0.86
Urological complications in renal transplantation from cadaveric donor grafts: a retrospective analysis of 20 years. Urol Int (2005) 0.86
[Testicular tumours in infancy and children]. Actas Urol Esp (2011) 0.85
Association of MICA-A5.1 allele with susceptibility to celiac disease in a family study. Am J Gastroenterol (2003) 0.84
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother (2009) 0.84
The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol (1998) 0.84
Soluble complement receptor type 1 (CD35) is released from leukocytes by surface cleavage. Eur J Immunol (1994) 0.84
Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation (2001) 0.84
The problem of late allograft loss in kidney transplantation. Minerva Urol Nefrol (2003) 0.83
Recombination and selection in the maintenance of the adaptive value of inversions. J Evol Biol (2010) 0.83
A naturally occurring human Nedd4-2 variant displays impaired ENaC regulation in Xenopus laevis oocytes. Am J Physiol Renal Physiol (2004) 0.83
PTGDR gene in asthma: a functional, genetic, and epigenetic study. Allergy (2011) 0.83
Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2013) 0.83
From nature to the laboratory: the impact of founder effects on adaptation. J Evol Biol (2012) 0.83
Recurrent collapsing glomerulopathy. Transplantation (1998) 0.83
Importance of tumoral markers in donors: study of prostate-specific antigen. Transplant Proc (2003) 0.83
A prospective evaluation of the immediate reproducibility of the signal-averaged ECG. Am Heart J (1991) 0.83
Rethinking the triggering inflammatory processes of chronic periaortitis. Nephron Exp Nephrol (2006) 0.82
Kinship analyses identify fish dispersal events on a temperate coastline. Proc Biol Sci (2014) 0.82
Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group. Breast Cancer Res Treat (1999) 0.82
Genetic variation in the spread of Drosophila subobscura from a nonequilibrium population. Evolution (2000) 0.82
Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant (2014) 0.82
Effect of donor-specific transfusions on the outcome of renal allografts in the cyclosporine era. Transpl Int (2006) 0.81
Primary lymphoma of the colon. Rev Esp Enferm Dig (2013) 0.81
Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. J Antimicrob Chemother (2008) 0.81
[Anorexia nervosa and the kidney]. Rev Med Suisse (2009) 0.81
Rapid activation of the alternative pathway of complement by extracorporeal membrane oxygenation. ASAIO J (1999) 0.80
Isolation of nine nuclear microsatellites in the common Mediterranean sea urchin, Paracentrotus lividus (Lamarck). Mol Ecol Resour (2009) 0.80
Fast liver catabolism of C1q in patients with paraproteinaemia and depletion of the classical pathway of complement. Clin Exp Immunol (1987) 0.80
Acute effects of insulin-like growth factor-I (IGF-I) on bone protein synthesis in rats. Biochim Biophys Acta (1994) 0.80
Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy. Transplantation (1997) 0.80
Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation (1996) 0.80
Gene flow and gene flux shape evolutionary patterns of variation in Drosophila subobscura. Heredity (Edinb) (2013) 0.80
A new allele within the transmembrane region of the human MICA gene with seven GCT repeats. Tissue Antigens (2002) 0.79
Effect of dark chocolate on renal tissue oxygenation as measured by BOLD-MRI in healthy volunteers. Clin Nephrol (2013) 0.79
Hsp70 protein levels and thermotolerance in Drosophila subobscura: a reassessment of the thermal co-adaptation hypothesis. J Evol Biol (2012) 0.79
New synthetic sulfated oligosaccharides prolong survival of cardiac xenografts by inhibiting release of heparan sulfate from endothelial cells. Transplantation (1996) 0.79
Isolation and characterization of microsatellite loci in Palinurus elephas. Mol Ecol Resour (2008) 0.79
Effect of Cyp27A1 gene dosage on atherosclerosis development in ApoE-knockout mice. FASEB J (2013) 0.79